Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients
AACR Annual Meeting
PUBLICATIONS
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
Inhibition of Fatty Acid Synthase in vitro and in vivo Reduces RSV Replication
Keystone Meeting – Pathogenesis of Respiratory Viruses
Characterization of small-molecule FASN inhibitors in preclinical tumor models
AACR-NCI-EORTC International Conference
Imidazopyridine-Based Fatty Acid Syhthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation
ACS Medicinal Chemistry Letters
